Haduvio Opportunity Positions Trevi (TRVI) for Multibagger Gains, Says Morgan Stanley

Core Insights - Trevi Therapeutics Inc. (NASDAQ:TRVI) is highlighted as a promising multibagger stock, with Morgan Stanley initiating coverage with an Overweight rating and an $18 price target [1][2] Group 1: Haduvio's Market Potential - Haduvio, Trevi's extended-release formulation of nalbuphine, is being developed to treat chronic cough, addressing a significant unmet medical need in a market with limited existing therapies [2][3] - The analyst estimates that Haduvio could represent a multi-billion-dollar opportunity for Trevi, with increasing interest in the pharmaceutical sector further supporting this potential [3] Group 2: Competitive Landscape - Large pharmaceutical companies like GSK and Merck have already engaged in billion-dollar partnerships in the chronic cough treatment space, indicating that Trevi could benefit from increased attention and investment in this area [3]